Results 171 to 180 of about 389,573 (268)
Preparing Adjuvanted Nanoliposomes for Applications Toward Recombinant Influenza Vaccine Development. [PDF]
Sia ZR +5 more
europepmc +1 more source
Abstract Our general interest is in global trade loss from livestock pathogens, specifically exports. We adopt a causal inference approach that considers animal disease outbreaks over time as non‐staggered binary treatments with the potential for switching in (infection) and out of treatment (recovery) within the sample period. The outcome evolution of
Mohammad Maksudur Rahman +1 more
wiley +1 more source
Advances in vaccine development through the controlled human infection models for hookworm and schistosomiasis. [PDF]
Hoogerwerf MA +4 more
europepmc +1 more source
Abstract Health inequalities persist along lines of income and wealth, shaped by unequal access to healthcare, differences in health behaviors, and pre‐existing chronic conditions. The COVID‐19 pandemic further put families in Korea under health strain and worsened their health outcomes.
Jaehyun Nam +3 more
wiley +1 more source
Applying principles of vaccine development to oncomicrobial vaccines. [PDF]
Despins CA, Viegas NJP, Holt RA.
europepmc +1 more source
Pathogenic PF4/Polyanion ELISA‐Negative Antibodies in HIT
ABSTRACT Background Platelet factor 4‐polyanion enzyme‐linked immunosorbent assays (ELISAs) are considered highly sensitive for diagnosing heparin‐induced thrombocytopenia (HIT), such that current practice guidelines recommend use of ELISA‐negative results to exclude HIT.
Adam J. Kanack +25 more
wiley +1 more source
Chikungunya Virus in 2025: Epidemiology, Immunopathogenesis, and Vaccine Development - A Narrative Review. [PDF]
Zhao C +5 more
europepmc +1 more source
ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker +6 more
wiley +1 more source
Recent Advances, Bottlenecks, and Future Directions in <i>Plasmodium falciparum</i> Vaccine Development. [PDF]
Turan G +5 more
europepmc +1 more source
We established that mixed DdCBE microinjection is an efficient, heritable, and precise strategy for generating multiplex mtDNA mutant rats. This advancement significantly expands the utility of DdCBEs for mitochondrial disease modeling, providing a robust platform for exploring the pathogenic mechanisms of complex mtDNA mutations and developing ...
Xu Zhang +14 more
wiley +1 more source

